metastatic/advanced RCC (mRCC) - 1st line (L1) | |
metastatic/advanced RCC (mRCC) - 1st line (L1) | |
pembrolizumab based treatment | |
pembrolizumab plus axitinib | KEYNOTE-426 |
pembrolizumab plus lenvatinib | KEYNOTE-581/CLEAR ... |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -